Riverain’s Chest X-Ray Comparison Tool Gets FDA Nod
Temporal Comparison software compares current and prior chest X-rays to help identify nodules that may be early-stage lung cancer.
Riverain Technologies, a Dayton, Ohio-based medical technology company, has received FDA 510(k) clearance for its Temporal Comparison software, which compares current and prior chest X-rays and can help identify nodules that may be early-stage lung cancer, the company announced.
The technology targets differences between the X-rays, drawing attention to what could be an emerging or enlarging tumor. The software aligns the two images to produce a difference image, which the company said allows radiologists to identify subtle changes more clearly.
In a study of 422 pairs of chest X-rays, 15 radiologists demonstrated an average of 12.4 percent improvement in sensitivity for actionable solitary pulmonary nodules using the software, compared to results viewing the X-rays side by side, the company said.
The software can be used with Riverain’s Bone Suppression software, which removes the bones from the image to make differences more conspicuous.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
